MitraClipTM TMVr

A better quality of
life is possible for your
patients with MR

MitraClip™ Therapy: A Minimally Invasive Option

MitraClip™ transcatheter mitral valve repair (TMVr) is a minimally invasive treatment option for patients with significant mitral regurgitation (MR) who are considered unable to have surgery.1

For Many, Surgery Is Contraindicated and Medications Are Not Sufficient

Approximately 50% of symptomatic patients with severe MR are not candidates for surgery due to underlying factors.* MR patients who most need intervention are often the most likely to be denied surgery.2

*Based on a survey of severely symptomatic MR patients in NYHA Class III-IV (n = 396); 10% had surgery the following year.
The remainder had no surgery; medical management only.

MitraClip™ TMVr Makes Intervention Possible for Your Patients with MR

Considerations for MitraClip candidates include1:

  • Significant MR (MR ≥ 3+)
  • Symptomatic
  • Surgical risk factors including age, frailty, or severe comorbidities such as liver disease and pulmonary hypertension

ESC/EACTS AND ESC/HF GUIDELINES FAVOR INTERVENTION

MitraClip therapy is the only transcatheter mitral valve repair therapy recommended by the 2017 ESC/EACTS and 2016 ESC/HF Guidelines.3-4 Determining the severity of MR is an important factor in the management of the condition. The guidelines support aggressive monitoring and early action, with the goal of preventing complications due to LV volume overload.3

IDENTIFYING PATIENTS FOR MITRACLIP™ THERAPY

MitraClip Transesophageal Echo (TEE) Screening Guide

Download Now

MitraClip Procedural Positioning and Imaging Guide

DOWNLOAD NOW

MitraClip Transthoracic Echo (TTE) Screening Guide

Download Now

MAT-2011219 v1.0 | Item approved for Global OUS use only.

References
  1. MitraClip G4 Clip Delivery System Instructions for Use.
  2. Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28(11):1358-1365.
  3. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease: The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;38(36):2739-2791.
  4. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975.

This site uses cookies to improve your experience.

To find out more please read our Privacy and Cookies policy.

Ok

Sign up

Receive updates from Abbott Structural Heart

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

YOU ARE ABOUT TO LEAVE
www.structural­heart­solutions.com

You are now leaving www.structuralheartsolutions.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.